45736-33-2

Basic information

• Product Name: (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione
• Synonyms: (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione
• CAS NO: 45736-33-2
• Molecular Formula: C₆H₇NO₃
• Molecular Weight: 141.12468
• Mol File: 45736-33-2.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione(45736-33-2)
• EPA Substance Registry System: (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione(45736-33-2)

Safety Data

• Hazardous Substances Data: 45736-33-2(Hazardous Substances Data)

Usage

Description

(7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione is a heterocyclic chemical compound with the molecular formula C5H5NO3. It features a pyrrolo-oxazole ring system and holds potential pharmaceutical applications due to its unique structure and properties. (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione may exhibit biological activity, making it a candidate for the development of new drugs. Further research and exploration of its properties could uncover its potential therapeutic uses.

Uses

Used in Pharmaceutical Industry:
(7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione is used as a chemical compound for potential pharmaceutical applications. Its unique structure and properties suggest that it may exhibit biological activity, which could be harnessed in the development of new drugs. (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione's potential therapeutic uses are yet to be fully explored and understood, indicating the need for further research in this area.
Used in Drug Development:
(7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione is used as a compound in drug development for its potential to exhibit biological activity. The exploration of its properties could lead to the creation of novel therapeutic agents, particularly in the pharmaceutical industry where innovative drug discovery is crucial. (7aS)-tetrahydro-1H,3H-Pyrrolo[1,2-c]oxazole-1,3-dione's unique structure may offer new avenues for treating various medical conditions, pending further investigation into its efficacy and safety.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 7776-34-3 L-proline hydrochloride 
• 67-66-3 chloroform 
• 147-85-3 L-proline 
• 503-38-8 trichloromethyl chloroformate 
• 131180-40-0 N-Chlorocarbonyl-L-proline 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 74761-41-4 (S)-1-(methoxycarbonyl)pyrrolidine-2-carboxylic acid 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 75-44-5 phosgene 

Downstream Products

• 169564-58-3 (3aS)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydro-2H-pyrrolo[2,1-e]azaborole 
• 22348-32-9 (S)-diphenylprolinol 
• 1352129-67-9 N-benzoyl-L-proline amide 
• 951008-65-4 {(2S)-2-{bis[3,5-bis(trifluoromethyl)phenyl]hydroxymethyl}-1-pyrrolidinyl}[4-(1-pyrrolidinyl)-3-pyridinyl]methanone 
• 951008-61-0 C₂₇H₁₇N₂O₂ClF₁₂ 
• 951008-60-9 C₂₇H₂₉N₂O₂Cl 
• 951008-59-6 C₂₇H₂₉N₂O₆Cl 
• 951008-58-5 C₄₇H₃₇N₂O₂Cl 
• 848821-76-1 (S)-(-)-α,α-bis[3,5-bis(trifluoromethyl)phenyl]-2-pyrrolidinemethanol 
• 951008-57-4 (S)-bis(3,5-dimethoxyphenyl)(pyrrolidin-2-yl)methanol 
• 951008-56-3 C₄₁H₃₅NO 
• 3705-27-9 (S)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione 
• 639838-02-1 α,α-di(4-bromophenyl)-L-prolinol 

Relevant articles and documents

Synthesis and Properties of High Molecular Weight Polypeptides Containing Proline

High-purity N-carboxy-L-proline anhydride (N-carboxy-2-pyrrolidinecarboxylic acid anhydride) was synthesized.We used triethylamine instead of expensive Ag2O to remove HCl during the synthesis.Copolypeptides with a random sequence of L-proline (Pro) with glycine, L-alanine (Ala), L-α-aminobutyric acid (Abu), L-Norvaline (Nva) or L-leucine (Leu) were synthesized by copolymerization of the corresponding N-carboxy-α-amino acid anhydrides in solution.Copolypeptides of Pro with Ala or Abu were partially soluble in water.However, the copolypeptides of proline with Nva or Leu with longer side chains were insoluble in water.The conformation of water-soluble copolymer at various pH was analyzed by circular dichroism (CD).The structures of the polypeptides in aqueous solution were almost independent of the pH, and were in a collagen-like conformation.

Thermoresponsive and Mechanical Properties of Poly(l -proline) Gels

Gelation of the left helical N-substituted homopolypeptide poly(l-proline) (PLP) in water was explored, employing rheological and small-angle scattering studies at different temperatures and concentrations in order to investigate the network structure and its mechanical properties. Stiff gels were obtained at 10 wt % or higher at 5 °C, the first time gelation has been observed for homopolypeptides. The secondary structure and helical rigidity of PLP has large structural similarities to gelatin but as gels the two materials show contrasting trends with temperature. With increasing temperature in D2O, the network stiffens, with broad scattering features of similar correlation length for all concentrations and molar masses of PLP. A thermoresponsive transition was also achieved between 5 and 35 °C, with moduli at 35 °C higher than gelatin at 5 °C. The brittle gels could tolerate strains of 1% before yielding with a frequency-independent modulus over the observed range, similar to natural proline-rich proteins, suggesting the potential for thermoresponsive or biomaterial-based applications.

METHOD FOR PRODUCING AMINO ACID-N-CARBOXYLIC ACID ANHYDRIDE

PROBLEM TO BE SOLVED: To provide: a method for safely and efficiently producing amino acid-N-carboxylic acid anhydride; and a method for producing peptide by using the obtained amino acid-N-carboxylic acid anhydride. SOLUTION: The method for producing an amino acid-N-carboxylic acid anhydride according to the present invention is characterized in that the amino acid-N-carboxylic acid anhydride is represented by the following formula (II), and a step of irradiating a composition containing a halogenated methane and an amino acid compound represented by the following formula (I) with high energy light in the presence of oxygen is included. [In the formula, R1 represents an amino acid side chain group in which the reactive group is protected, and R2 represents H or the like.]. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

Oxazolidinone compound as well as preparation method, application and pharmaceutical composition thereof

The invention relates to an oxazolidinone compound used as an Lp-PLA2 covalent inhibitor and a pharmaceutical composition of the oxazolidinone compound, the structure of the oxazolidinone compound isshown as a general formula I, and R1, R2 and R3 are defined as the specification and claims. The compound shown in the general formula I or the stereoisomer or the pharmaceutically acceptable salt thereof can be used as the Lp-PLA2 covalent inhibitor to prevent and/or treat and/or improve diseases related to Lp-PLA2 enzyme activity. Meanwhile, the stereoisomer or the pharmaceutically acceptable salt of the compound shown in the general formula I can be used as an Lp-PLA2 specific molecular probe.